Our study may serve as a rationale for targeting the HCC-intrinsic Galectin-3-β-catenin signalling in a novel therapeutic application to treat metastatic or sorafenib-resistant patients. This evidence concerns the gene LGALS3 and hepatocellular carcinoma.